Literature DB >> 24787227

Evaluation of ZAR1 and SFRP4 methylation status as potentials biomarkers for diagnosis in cervical cancer: exploratory study phase I.

Priscilla Brebi1, Rene Hoffstetter, Alejandra Andana, Carmen G Ili, Kathleen Saavedra, Tamara Viscarra, Javier Retamal, Raul Sanchez, Juan C Roa.   

Abstract

CONTEXT: Aberrant hypermethylation of promoter region of tumor suppressor genes could be used as cancer biomarkers.
OBJECTIVE: To test methylation status of ZAR1 and SFRP4 promoter regions as potentials biomarkers for diagnosis of preneoplastic and neoplastic lesions of cervix.
MATERIALS AND METHODS: Cytobrush samples were evaluated by Methylation specific PCR (MSP) and quantitative MSP (qMSP).
RESULTS: ZAR1 and SFRP4 methylation frequency increased as the grade of lesion increased and the differences between normal and cervical cancer (CC) are statistically significant (p < 0.0001). qMSP showed higher ZAR1 and SFRP4 methylation levels in cancer than normal epithelia (p < 0.001) and preneoplastics lesions (p < 0.01). DISCUSSION: qMSP quantify methylation levels and have high sensitivity and specificity.
CONCLUSION: ZAR1 and SFRP4 qMSP could be used as potential biomarker for CC diagnosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24787227     DOI: 10.3109/1354750X.2013.867535

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  9 in total

1.  Systematic prediction of target genes and pathways in cervical cancer from microRNA expression data.

Authors:  Rui Chen; Yong-Hua Shi; Hong Zhang; Jian-Yun Hu; Yi Luo
Journal:  Oncol Lett       Date:  2018-04-25       Impact factor: 2.967

2.  FANCF hypomethylation is associated with colorectal cancer in Han Chinese.

Authors:  Hang Yu; Ranran Pan; Tong Gao; Dongping Wu; Jieer Ying; Shiwei Duan
Journal:  Turk J Gastroenterol       Date:  2020-08       Impact factor: 1.852

3.  Antagonizing canonical Wnt signaling pathway by recombinant human sFRP4 purified from E. coli and its implications in cancer therapy.

Authors:  Archita Ghoshal; Siddhartha Sankar Ghosh
Journal:  Mol Cell Biochem       Date:  2016-06-23       Impact factor: 3.396

4.  miR-942 promotes cancer stem cell-like traits in esophageal squamous cell carcinoma through activation of Wnt/β-catenin signalling pathway.

Authors:  Chunlei Ge; Shikai Wu; Weiwei Wang; Zhimin Liu; Jianhua Zhang; Zhenyu Wang; Ruilei Li; Zhiwei Zhang; Zhen Li; Suwei Dong; Ying Wang; Yuanbo Xue; Jinyan Yang; Qinghua Tan; Ziping Wang; Xin Song
Journal:  Oncotarget       Date:  2015-05-10

5.  Epigenetic therapy of novel tumour suppressor ZAR1 and its cancer biomarker function.

Authors:  Verena Deutschmeyer; Janina Breuer; Sara K Walesch; Anna M Sokol; Johannes Graumann; Marek Bartkuhn; Thomas Boettger; Oliver Rossbach; Antje M Richter
Journal:  Clin Epigenetics       Date:  2019-12-04       Impact factor: 6.551

6.  Markers of Angiogenesis, Lymphangiogenesis, and Epithelial-Mesenchymal Transition (Plasticity) in CIN and Early Invasive Carcinoma of the Cervix: Exploring Putative Molecular Mechanisms Involved in Early Tumor Invasion.

Authors:  Olga Kurmyshkina; Pavel Kovchur; Ludmila Schegoleva; Tatyana Volkova
Journal:  Int J Mol Sci       Date:  2020-09-06       Impact factor: 5.923

7.  Tumor suppressor role of sFRP‑4 in hepatocellular carcinoma via the Wnt/β‑catenin signaling pathway.

Authors:  Quanxin Wu; Cheng Xu; Xianghua Zeng; Zhimin Zhang; Bo Yang; Zhiguo Rao
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

Review 8.  The Relevance of Gender in Tumor-Influencing Epigenetic Traits.

Authors:  Victoria Sarne; Sandrina Braunmueller; Lisa Rakob; Rita Seeboeck
Journal:  Epigenomes       Date:  2019-01-28

9.  Reprimo as a modulator of cell migration and invasion in the MDA-MB-231 breast cancer cell line.

Authors:  Kurt Buchegger; Carmen Ili; Ismael Riquelme; Pablo Letelier; Alejandro H Corvalán; Priscilla Brebi; Tim Hui-Ming Huang; Juan Carlos Roa
Journal:  Biol Res       Date:  2016-01-22       Impact factor: 5.612

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.